TheraRadar
Clinical-Stage Companies / Latigo Biotherapeutics

Latigo Biotherapeutics

Pre-Approval PRO BETA
6
Total Trials
0
Phase 3
2
Phase 2
2
Recruiting
43
Score

Pipeline by Phase

Phase 3
Phase 2
2
Phase 1
4

Therapeutic Focus

Healthy Acute Pain Postoperative Pain Control Healthy Participants Pain Management

Clinical Trials (6)

NCT07102459 Phase 2 COMPLETED

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

Started: 7/24/2025

NCT06774625 Phase 2 COMPLETED

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

Started: 12/19/2024

NCT07110610 Phase 1 RECRUITING

Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants

Started: 9/3/2025

NCT06049095 Phase 1 RECRUITING

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Started: 10/17/2023

NCT07341152 Phase 1 COMPLETED

A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants

Started: 10/6/2025

NCT06554574 Phase 1 COMPLETED

A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants

Started: 9/3/2024

Drug Candidates

Experimental: LTG-001 High Dose Experimental: LTG-001 Low Dose Active Comparator: HB/APAP Placebo Comparator LTG-321 LTG-001 Placebo LTG-001 SDD LTG-001 Formulation A Prototype 1 LTG-001 Formulation B Prototype 2
Activity Status: Active
Last Trial Started: 10/6/2025
Last Trial Ended: 1/7/2026
Trials (12 months): 3
Completed Trials: 4
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.